Sign Out
There is no experience with overdose in patients with neuromyelitis optica (NMO) or NMOSD. A single dose of up to 240 mg Enspryng was administered subcutaneously to healthy adult volunteers in a phase I study and no serious or severe adverse events were observed in the study.
In the event of an overdose, the patient should be closely supervised, treated symptomatically, and supportive measures instituted as required.
